For the most part, developing new medical technologies is a huge benefit to people. Take for instance the smart pill that the U.S. Food and Drug Administration (FDA) just approved, which is meant to monitor if patients are sticking to their medication schedule. While incredibly useful, it could also allow entities like the U.S. government to spy on its citizens even more intrusively than it does now.
No one likes to be spied on and yet this is exactly what concerned privacy groups are saying could happen with the digital pill that the FDA just approved for use. Called the Abilify MyCite, the pill comes with sensors that basically indicate if patients just took their medication, Futurism reports.
Abilify is a drug used to treat neurological conditions such as schizophrenia and bipolar disorders. The sensor is embedded in the pill, where it will send out a signal once it comes in contact with the stomach. This signal will be picked up by a patch on the patient’s left rib cage, which will then notify the monitoring personnel via the accompanying app.
The information that the sensors can send out can include the dosage, the exact time when the pill was taken, and even what the patient was doing at the time. Because of how intrusive the data mining process appears, groups concerned about potential abuses are speaking out. They are especially worried about potential punitive actions against patients who are committing what’s called nonadherence.
Basically, nonadherence or noncompliance refers to patients not taking their medication as they are supposed to. This leads to patients getting sicker, which then leads to higher medical costs due to the increased medical attention that they need. Apparently, this particular trend costs $100 billion a year, the New York Times reports.
There’s also the concern of medical professionals that a smart pill could lead to a feeling of coercion on the part of the patients. Subjects could feel pressured to take their medication because their doctors are monitoring them.


Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Quantum Systems Projects Revenue Surge as It Eyes IPO or Private Sale
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts
Nexperia Urges China Division to Resume Chip Production as Supply Risks Mount
NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp
Samsung Launches Galaxy Z TriFold to Elevate Its Position in the Foldable Smartphone Market
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation
FDA Pilot Program Eases Rules for Nicotine Pouch Makers
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Baidu Cuts Jobs as AI Competition and Ad Revenue Slump Intensify
AI-Guided Drones Transform Ukraine’s Battlefield Strategy
Apple Appoints Amar Subramanya as New Vice President of AI Amid Push to Accelerate Innovation 



